

AMENDMENTS TO THE SPECIFICATION

Please replace the paragraph encompassing lines 7-24, at page 23 of the specification, with the following paragraph:

[³H]PGD₂ binding assay described in Example 3 was carried out in the presence of various unlabeled prostanoids (products of Cayman), and the binding affinity of human CRTH2 to various prostanoids was evaluated. As a result, the order of the degree of the binding affinity of prostanoids to human CRTH2 was determined as follows: PGD₂ ≥ 13,14-dihydro-15-keto ~~PGD₂~~ 13,14-dehydro-15-keto PGD₂ >> prostaglandin J₂ (PGJ₂) > 15-deoxydelta 12,14-PGJ₂ ≥ prostaglandin E₂ (PGE₂) = prostaglandin A₂ (PGA₂) >> thromboxane B₂ (TXB₂) (Fig. 3). For comparison, the order of the degree of the binding affinity of prostanoids to the DP receptor was determined as follows: PGD₂ = PGJ₂ >> PGE₂ > 13,14-dihydro-15-keto PGD₂ ~~13,14-dehydro-15-keto PGD₂~~ > 15-deoxydelta 12,14-PGJ₂ ≥ TXB₂ ≥ PGA₂. These results show that the degree of the binding affinity of human CRTH2 to PGD₂ is equal to that of the binding affinity of the DP receptor to PGD₂, and that a great difference exists between human CRTH2 and the DP receptor in the degree of binding affinity to other prostanoids, such as 13,14-dehydro-15-keto PGD₂.